Compound nanoscale drug delivery system and application thereof in gynecological tumor treatment

A drug delivery system and technology for gynecological tumors, applied in the field of biomedicine, can solve the problems of reducing the therapeutic effect of liposomes, reducing the stability of liposomes, and easy leakage of liposomes, so as to enhance the anti-tumor effect and increase the target To inhibit and weaken the effect of toxic and side effects

Active Publication Date: 2020-01-10
湖北绿无界生物科技有限公司
View PDF7 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

And because the preparation process is relatively simple, the material is easy to get (such as soybean phospholipids existing for the approval of pharmaceutical excipients for injection), some dosage forms have entered in

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Compound nanoscale drug delivery system and application thereof in gynecological tumor treatment

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0059] The present embodiment provides a composite nano drug delivery system, comprising: (a) paclitaxel and curcumin composition as an active ingredient; (b) miRNA-HA as a targeting material; (c) carboxylated magnetic Mesoporous silica;

[0060] The concentration of paclitaxel in the active ingredient is 5mg / mL, the concentration of the curcumin is 50ng / mL; the concentration of the targeting material is 20mg / mL; the targeting material and carboxylated magnetic mesoporous dioxide The mass ratio of silicon is 1:1; the molecular weight of the sodium hyaluronate is 37KDa; the miRNA is miR-124, and the sequence of the miR-124 is uaaggcacgcggugaaugcc.

[0061] The preparation method of the magnetic mesoporous silica of described carboxylation, comprises the steps:

[0062] a) Magnetic core (Fe 3 o 4 ) preparation:

[0063] Use a 250mL three-neck flask, add 120mL of distilled water, pass nitrogen, and then add 4.81g of FeCl to the flask 3 .6H 2 O and 2.12gFeCl 2 .4H 2 O, sti...

Embodiment 2

[0081] This embodiment provides a composite nano drug delivery system. Compared with Embodiment 1, the difference is that only paclitaxel is used as the active ingredient, and the concentration of paclitaxel in the active ingredient is 5 mg / mL.

[0082] All the other are the same as Example 1.

Embodiment 3

[0084] This example provides a composite nano drug delivery system. Compared with Example 1, the difference is that only curcumin is used as the active ingredient, and the concentration of curcumin in the active ingredient is 50 ng / mL.

[0085] All the other are the same as Example 1.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
The average particle sizeaaaaaaaaaa
Molecular weightaaaaaaaaaa
Login to view more

Abstract

The invention discloses a compound nanoscale drug delivery system and application thereof in gynecological tumor treatment. The compound nanoscale drug delivery system comprises (a) a paclitaxel and curcumin composition serving as an active component, (b) miRNA-HA serving as a targeted material, and (c) carboxylated magnetic mesoporous silica serving as a carrier. According to the compound nanoscale drug delivery system, the carboxylated magnetic mesoporous silica serves as the drug carrier, on one hand, a high drug encapsulation capacity is ensured, and on the other hand, modifiable sites areprovided for modification of functional groups; and through modification of the targeted material miRNA-HA, the tumor cell targeting capability and gynecological tumor cell targeted inhibition of thecarboxylated magnetic mesoporous silica nanoscale drug delivery system can be improved, and the inhibition rate of tumor cell migration and invasion is increased. The compound nanoscale drug deliverysystem is reasonable in method design and simple in preparation technology and thus has wide application prospects, and a foundation is also laid for design and development of corresponding drug delivery systems.

Description

technical field [0001] The invention relates to the technical field of biomedicine, in particular to a composite nano drug delivery system and its application in the treatment of gynecological tumors. Background technique [0002] Ovarian cancer is one of the most common gynecological tumors, and its incidence rate ranks third after cervical cancer and uterine body cancer. Ovarian cancer not only has a very high incidence rate, but also has the highest mortality rate among malignant tumors of the female reproductive system, which has seriously affected the health of women and the happiness of countless families: at present, the incidence rate of ovarian cancer in my country is 8.14 / 10 million, the death rate was 3.13 / 100,000. Ovarian cancer is not easy to be diagnosed at an early stage, so about 70% of patients have been diagnosed at an advanced stage when they first see a doctor, which makes the effective treatment of the disease face a huge challenge, and according to dome...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K9/51A61K47/04A61K47/02A61K47/36A61K47/61A61K47/52A61K31/337A61K31/12A61K31/7105A61P35/00A61P35/04
CPCA61K9/5115A61K9/5161A61K9/5192A61K31/12A61K31/337A61K31/7105A61K47/52A61K47/61A61P35/00A61P35/04A61K2300/00
Inventor 孙强张文艳
Owner 湖北绿无界生物科技有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap